Systematic literature review and clinical validation of circulating microRNAs as diagnostic biomarkers for colorectal cancer

Oncotarget

Volumn 8, Issue 40, 2017, Pages 68317-68328

  Pan, Cheng ^a,b   Yan, Xuebing ^a   Li, Hao ^a   Huang, Linsheng ^a   Yin, Mingming ^a   Yang, Yongzhi ^a   Gao, Renyuan ^a   Hong, Leiming ^a,c   Ma, Yanlei ^a   Shi, Chenzhang ^a   Qin, Huanlong ^a   Zhang, Peng ^a  

^a TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c WEIHAI MUNICIPAL HOSPITAL   (China)

Author keywords

Biomarkers; Circulating microRNAs; Colorectal cancer; Diagnosis

Indexed keywords

EID: 85046375377     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.19344     Document Type: Article

References (57)

1. Siegel R, DeSantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 104-17. https://doi.org/10.3322/caac.21220.
2. Thomas DS, Fourkala EO, Apostolidou S, Gunu R, Ryan A, Jacobs I, Menon U, Alderton W, Gentry-Maharaj A, Timms JF. Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples. Br J Cancer. 2015; 113: 268-74. https://doi.org/10.1038/bjc.2015.202.
3. Aghagolzadeh P, Radpour R. New trends in molecular and cellular biomarker discovery for colorectal cancer. World J Gastroenterol. 2016; 22: 5678-93. https://doi.org/10.3748/wjg.v22.i25.5678.
4. Svoronos AA, Engelman DM, Slack FJ. OncomiR or tumor suppressor? The duplicity of MicroRNAs in cancer. Cancer Res. 2016; 76: 3666-70. https://doi.org/10.1158/0008-5472. CAN-16-0359.
5. Ma Y, Zhang P, Wang F, Zhang H, Yang Y, Shi C, Xia Y, Peng J, Liu W, Yang Z, Qin H. Elevated oncofoetal miR-17-5p expression regulates colorectal cancer progression by repressing its target gene P130. Nat Commun. 2012; 3: 1291. https://doi.org/10.1038/ncomms2276.
6. Wang F, Ma YL, Zhang P, Shen TY, Shi CZ, Yang YZ, Moyer MP, Zhang HZ, Chen HQ, Liang Y, Qin HL. SP1 mediates the link between methylation of the tumour suppressor miR-149 and outcome in colorectal cancer. J Pathol. 2013; 229: 12-24. https://doi.org/10.1002/path.4078.
7. Ma Y, Zhang P, Wang F, Zhang H, Yang J, Peng J, Liu W, Qin H. miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut. 2012; 61: 1447-53. https://doi.org/10.1136/gutjnl-2011-301122.
8. Feng J, Yang Y, Zhang P, Wang F, Ma Y, Qin H, Wang Y. miR-150 functions as a tumour suppressor in human colorectal cancer by targeting c-Myb. J Cell Mol Med. 2014; 18: 2125-34. https://doi.org/10.1111/jcmm.12398.
9. Shi C, Yang Y, Xia Y, Okugawa Y, Yang J, Liang Y, Chen H, Zhang P, Wang F, Han H, Wu W, Gao R, Gasche C, et al. Novel evidence for an oncogenic role of microRNA-21 in colitis-associated colorectal cancer. Gut. 2016; 65: 1470-80. https://doi.org/10.1136/gutjnl-2014-308455.
10. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K. The microRNA spectrum in 12 body fluids. Clin Chem. 2010; 56: 1733-41. https://doi.org/10.1373/clinchem.2010.147405.
11. Xiao YF, Yong X, Fan YH, Lu MH, Yang SM, Hu CJ. microRNA detection in feces, sputum, pleural effusion and urine: novel tools for cancer screening (Review). Oncol Rep. 2013; 30: 535-44. https://doi.org/10.3892/or.2013.2525.
12. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009; 58: 1375-81. https://doi.org/10.1136/gut.2008.167817.
13. Kanaan Z, Rai SN, Eichenberger MR, Roberts H, Keskey B, Pan J, Galandiuk S. Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg. 2012; 256: 544-51. https://doi.org/10.1097/SLA.0b013e318265bd6f.
14. Liu GH, Zhou ZG, Chen R, Wang MJ, Zhou B, Li Y, Sun XF. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biol. 2013; 34: 2175-81. https://doi.org/10.1007/ s13277-013-0753-8.
15. Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye S, Ling S, Jiang L, Tian Y, Lin TY. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol. 2010; 25: 1674-80. https://doi.org/10.1111/j.1440-1746.2010.06417.x.
16. Cheng G. Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev. 2015; 81: 75-93. https://doi.org/10.1016/j.addr.2014.09.001.
17. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, Tait JF, Tewari M. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila). 2012; 5: 492-7. https://doi.org/10.1158/1940-6207.CAPR-11-0370.
18. Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 2013; 105: 849-59. https://doi.org/10.1093/jnci/djt101.
19. Fang Z, Tang J, Bai Y, Lin H, You H, Jin H, Lin L, You P, Li J, Dai Z, Liang X, Su Y, Hu Q, et al. Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma. J Exp Clin Cancer Res. 2015; 34: 86. https://doi.org/10.1186/ s13046-015-0198-6.
20. Wang J, Huang SK, Zhao M, Yang M, Zhong JL, Gu YY, Peng H, Che YQ, Huang CZ. Identification of a circulating microRNA signature for colorectal cancer detection. PLoS One. 2014; 9: e87451. https://doi.org/10.1371/journal.pone.0087451.
21. Giraldez MD, Lozano JJ, Ramirez G, Hijona E, Bujanda L, Castells A, Gironella M. Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. Clin Gastroenterol Hepatol. 2013; 11: 681-8. -e3. https://doi.org/10.1016/j.cgh.2012.12.009.
22. Kanaan Z, Roberts H, Eichenberger MR, Billeter A, Ocheretner G, Pan J, Rai SN, Jorden J, Williford A, Galandiuk S. A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer. Ann Surg. 2013; 258: 400-8. https://doi.org/10.1097/SLA.0b013e3182a15bcc.
23. Faltejskova P, Bocanek O, Sachlova M, Svoboda M, Kiss I, Vyzula R, Slaby O. Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: evidence against their usage as biomarkers in colorectal cancer. Cancer Biomark. 2012; 12: 199-204. https://doi.org/10.3233/CBM-130308.
24. Brunet Vega A, Pericay C, Moya I, Ferrer A, Dotor E, Pisa A, Casalots A, Serra-Aracil X, Oliva JC, Ruiz A, Saigi E. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. Oncol Rep. 2013; 30: 320-6. https://doi.org/10.3892/or.2013.2475.
25. Wang B, Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol. 2012; 138: 1659-66. https://doi.org/10.1007/s00432-012-1244-9.
26. Nonaka R, Nishimura J, Kagawa Y, Osawa H, Hasegawa J, Murata K, Okamura S, Ota H, Uemura M, Hata T, Takemasa I, Mizushima T, Okuzaki D, et al. Circulating miR-199a-3p as a novel serum biomarker for colorectal cancer. Oncol Rep. 2014; 32: 2354-8. https://doi.org/10.3892/or.2014.3515.
27. Basati G, Emami Razavi A, Abdi S, Mirzaei A. Elevated level of microRNA-21 in the serum of patients with colorectal cancer. Med Oncol. 2014; 31: 205. https://doi.org/10.1007/s12032-014-0205-3.
28. Zanutto S, Pizzamiglio S, Ghilotti M, Bertan C, Ravagnani F, Perrone F, Leo E, Pilotti S, Verderio P, Gariboldi M, Pierotti MA. Circulating miR-378 in plasma: a reliable, haemolysisindependent biomarker for colorectal cancer. Br J Cancer. 2014; 110: 1001-7. https://doi.org/10.1038/bjc.2013.819.
29. Du M, Liu S, Gu D, Wang Q, Zhu L, Kang M, Shi D, Chu H, Tong N, Chen J, Adams TS, Zhang Z, Wang M. Clinical potential role of circulating microRNAs in early diagnosis of colorectal cancer patients. Carcinogenesis. 2014; 35: 2723-30. https://doi.org/10.1093/carcin/bgu189.
30. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010; 127: 118-26. https://doi.org/10.1002/ijc.25007.
31. Hofsli E, Sjursen W, Prestvik WS, Johansen J, Rye M, Trano G, Wasmuth HH, Hatlevoll I, Thommesen L. Identification of serum microRNA profiles in colon cancer. Br J Cancer. 2013; 108: 1712-9. https://doi.org/10.1038/bjc.2013.121.
32. Aherne ST, Madden SF, Hughes DJ, Pardini B, Naccarati A, Levy M, Vodicka P, Neary P, Dowling P, Clynes M. Circulating miRNAs miR-34a and miR-150 associated with colorectal cancer progression. BMC Cancer. 2015; 15: 329. https://doi.org/10.1186/s12885-015-1327-5.
33. Yuan D, Li K, Zhu K, Yan R, Dang C. Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer. Cancer Biol Ther. 2015; 16: 268-75. https://doi.org/10.1080/15384047.2014.1002327.
34. Basati G, Razavi AE, Pakzad I, Malayeri FA. Circulating levels of the miRNAs, miR-194, and miR-29b, as clinically useful biomarkers for colorectal cancer. Tumour Biol. 2016; 37: 1781-8. https://doi.org/10.1007/s13277-015-3967-0.
35. Yu J, Jin L, Jiang L, Gao L, Zhou J, Hu Y, Li W, Zhi Q, Zhu X. Serum miR-372 is a diagnostic and prognostic biomarker in patients with early colorectal cancer. Anticancer Agents Med Chem. 2016; 16: 424-31.
36. Liu M, Zhi Q, Wang W, Zhang Q, Fang T, Ma Q. Up-regulation of miR-592 correlates with tumor progression and poor prognosis in patients with colorectal cancer. Biomed Pharmacother. 2015; 69: 214-20. https://doi.org/10.1016/j.biopha.2014.12.001.
37. Wang Q, Huang Z, Ni S, Xiao X, Xu Q, Wang L, Huang D, Tan C, Sheng W, Du X. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One. 2012; 7: e44398. https://doi.org/10.1371/journal.pone.0044398.
38. Luo X, Stock C, Burwinkel B, Brenner H. Identification and evaluation of plasma microRNAs for early detection of colorectal cancer. PLoS One. 2013; 8: e62880. https://doi.org/10.1371/journal.pone.0062880.
39. Yamada A, Horimatsu T, Okugawa Y, Nishida N, Honjo H, Ida H, Kou T, Kusaka T, Sasaki Y, Yagi M, Higurashi T, Yukawa N, Amanuma Y, et al. Serum miR-21, miR-29a, and miR-125b are promising biomarkers for the early detection of colorectal neoplasia. Clin Cancer Res. 2015; 21: 4234-42. https://doi.org/10.1158/1078-0432.CCR-14-2793.
40. Ma YL, Zhang P, Wang F, Moyer MP, Yang JJ, Liu ZH, Peng JY, Chen HQ, Zhou YK, Liu WJ, Qin HL. Human embryonic stem cells and metastatic colorectal cancer cells shared the common endogenous human microRNA-26b. J Cell Mol Med. 2011; 15: 1941-54. https://doi.org/10.1111/j.1582-4934.2010.01170.x.
41. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105: 10513-8. https://doi.org/10.1073/pnas.0804549105.
42. Kawaguchi T, Komatsu S, Ichikawa D, Tsujiura M, Takeshita H, Hirajima S, Miyamae M, Okajima W, Ohashi T, Imamura T, Kiuchi J, Konishi H, Shiozaki A, et al. Circulating microRNAs: a next-generation clinical biomarker for digestive system cancers. Int J Mol Sci. 2016; 17: 1459. https://doi.org/10.3390/ijms17091459.
43. Ren A, Dong Y, Tsoi H, Yu J. Detection of miRNA as noninvasive biomarkers of colorectal cancer. Int J Mol Sci. 2015; 16: 2810-23. https://doi.org/10.3390/ijms16022810.
44. Yi R, Li Y, Wang FL, Miao G, Qi RM, Zhao YY. MicroRNAs as diagnostic and prognostic biomarkers in colorectal cancer. World J Gastrointest Oncol. 2016; 8: 330-40. https://doi.org/10.4251/wjgo.v8.i4.330.
45. Li J, Chen Y, Guo X, Zhou L, Jia Z, Tang Y, Lin L, Liu W, Ren C. Inhibition of miR-15b decreases cell migration and metastasis in colorectal cancer. Tumour Biol. 2016; 37: 8765-73. https://doi.org/10.1007/s13277-015-4396-9.
46. Wang W, Ji G, Xiao X, Chen X, Qin WW, Yang F, Li YF, Fan LN, Xi WJ, Huo Y, Wen WH, Yang AG, Wang T. Epigenetically regulated miR-145 suppresses colon cancer invasion and metastasis by targeting LASP1. Oncotarget. 2016; 7: 68674-87. https://doi.org/10.18632/oncotarget.11919.
47. Benderska N, Dittrich AL, Knaup S, Rau TT, Neufert C, Wach S, Fahlbusch FB, Rauh M, Wirtz RM, Agaimy A, Srinivasan S, Mahadevan V, Rummele P, et al. miRNA-26b overexpression in ulcerative colitis-associated carcinogenesis. Inflamm Bowel Dis. 2015; 21: 2039-51. https://doi.org/10.1097/MIB.0000000000000453.
48. Xi XP, Zhuang J, Teng MJ, Xia LJ, Yang MY, Liu QG, Chen JB. MicroRNA-17 induces epithelial-mesenchymal transition consistent with the cancer stem cell phenotype by regulating CYP7B1 expression in colon cancer. Int J Mol Med. 2016; 38: 499-506. https://doi.org/10.3892/ijmm.2016.2624.
49. Chen H, Liu H, Zou H, Chen R, Dou Y, Sheng S, Dai S, Ai J, Melson J, Kittles RA, Pirooznia M, Liptay MJ, Borgia JA, et al. Evaluation of plasma miR-21 and miR-152 as diagnostic biomarkers for common types of human cancers. J Cancer. 2016; 7: 490-9. https://doi.org/10.7150/jca.12351.
50. Carter JV, Roberts HL, Pan J, Rice JD, Burton JF, Galbraith NJ, Eichenberger MR, Jorden J, Deveaux P, Farmer R, Williford A, Kanaan Z, Rai SN, et al. A highly predictive model for diagnosis of colorectal neoplasms using plasma microRNA: improving specificity and sensitivity. Ann Surg. 2016; 264: 575-84. https://doi.org/10.1097/SLA.0000000000001873.
51. Montagnana M, Benati M, Danese E, Minicozzi AM, Paviati E, Gusella M, Pasini F, Bovo C, Guidi GC, Lippi G. Plasma expression levels of circulating miR-21 are not useful for diagnosing and monitoring colorectal cancer. Clin Lab. 2016; 62: 967-70.
52. Zekri AR, Youssef AS, Lotfy MM, Gabr R, Ahmed OS, Nassar A, Hussein N, Omran D, Medhat E, Eid S, Hussein MM, Ismail MY, Alenzi FQ, et al. Circulating serum miRNAs as diagnostic markers for colorectal cancer. PLoS One. 2016; 11: e0154130. https://doi.org/10.1371/journal.pone.0154130.
53. Cristobal I, Manso R, Gonzalez-Alonso P, Madoz-Gurpide J, Rojo F, Garcia-Foncillas J. Clinical value of miR-26b discriminating ulcerative colitis-associated colorectal cancer in the subgroup of patients with metastatic disease. Inflamm Bowel Dis. 2015; 21: E24-5. https://doi.org/10.1097/MIB.0000000000000572.
54. Rokkas T, Kothonas F, Rokka A, Koukoulis G, Symvoulakis E. The role of circulating microRNAs as novel biomarkers in diagnosing colorectal cancer: a meta-analysis. Eur J Gastroenterol Hepatol. 2015; 27: 819-25. https://doi.org/10.1097/MEG.0000000000000363.
55. Wang R, Wen H, Xu Y, Chen Q, Luo Y, Lin Y, Luo Y, Xu A. Circulating microRNAs as a novel class of diagnostic biomarkers in gastrointestinal tumors detection: a meta-analysis based on 42 articles. PLoS One. 2014; 9: e113401. https://doi.org/10.1371/journal.pone.0113401.
56. Nian J, Sun X, Ming S, Yan C, Ma Y, Feng Y, Yang L, Yu M, Zhang G, Wang X. Diagnostic accuracy of methylated SEPT9 for blood-based colorectal cancer detection: a systematic review and meta-analysis. Clin Transl Gastroenterol. 2017; 8: e216. https://doi.org/10.1038/ctg.2016.66.
57. Zhang J, Song Y, Zhang C, Zhi X, Fu H, Ma Y, Chen Y, Pan F, Wang K, Ni J, Jin W, He X, Su H, et al. Circulating miR-16-5p and miR-19b-3p as two novel potential biomarkers to indicate progression of gastric cancer. Theranostics. 2015; 5: 733-45. https://doi.org/10.7150/thno.10305.